Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

brompheniramine maleate

BROMPHENIRAMINE MALEATE

brompheniramine maleate (BROMPHENIRAMINE MALEATE) is a histamine h1 receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 12
Pipeline programs 2
News articles 0
Drug details — brompheniramine maleate
US status
approved
Class
—
Route
INJECTION
Patents
12
Programs
2
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

brompheniramine maleate (BROMPHENIRAMINE MALEATE) is a histamine h1 receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN brompheniramine maleate
Brand BROMPHENIRAMINE MALEATE
Mechanism Histamine H1 receptor antagonist
Target Histamine H1 receptor
Route INJECTION
Formulation TABLET
Originator Teva Pharma GmbH

Mechanism of action

Histamine H1 receptor antagonist

Primary target: Histamine H1 receptor

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. Dextromethorphan HBr Phase 1 · Kailera Therapeutics · Healthy
  2. dextromethorphan Unknown · Ultragenyx UK · Rett Syndrome

Related & competitor drugs

Browse all drugs
  1. azelastine hydrochloride Histamine H1 receptor antagonist
  2. carbinoxamine maleate Histamine H1 receptor antagonist
  3. cetirizine hydrochloride Histamine H1 receptor antagonist
  4. chlorpheniramine maleate Histamine H1 receptor antagonist
  5. clemastine fumarate Histamine H1 receptor antagonist
  6. cyproheptadine hydrochloride Histamine H1 receptor antagonist

Related patents

Browse patents Teva Pharma GmbH patent hub

  1. US 12077549

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11612608

    Methods of treating oral mucositis

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11066433

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10610533

    Methods of treating oral mucositis

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10597415

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10350193

    Super-oxide dismutase mimetics

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9855279

    Methods of treating oral mucositis

    Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9738669

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9738670

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9642861

    Methods of treating oral mucositis

    Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9353069

    Super-oxide dismutase mimetics

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8486928

    Super-oxide dismutase mimetics

    Expires Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is brompheniramine maleate?

brompheniramine maleate (BROMPHENIRAMINE MALEATE) is a histamine h1 receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for brompheniramine maleate?

BROMPHENIRAMINE MALEATE is a marketed brand name for brompheniramine maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of brompheniramine maleate?

brompheniramine maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.